Letter to the Editor: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?

Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?

“…The remaining authors have no conflicts to report. Maria C. Plaz Torres 1 Ariel Jaffe 2 Rachel Perry 2,3,4 Elisa Marabotto 1 Mario Strazzabosco 2 Edoardo G. Giannini 1…”

“…We thank Dr. Patoulias for their interest in our review article that assessed the complex interplay between medications for diabetes and the risk of HCC. [1,2] In his comments to our study, he raises an important issue related to a sort of positive "off-target activity" of novel drugs used in the management of type 2 diabetes, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs).…”

“…[4,5] Thus, we concur with the view expressed by Dr. Patoulias in his comment that the time is ripe to assess all the potential of these drugs in dedicated, prospective studies with solid outcomes in patients with chronic liver disease so as to evaluate whether they can be regarded as game-changers in the management of these patients. [1]…”